Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19 (ARCADIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04516759
Recruitment Status : Recruiting
First Posted : August 18, 2020
Last Update Posted : November 9, 2020
Sponsor:
Information provided by (Responsible Party):
St George Street Capital

Brief Summary:
The ARCADIA Trial is a randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in patients with either Type 1 or Type 2 diabetes, hospitalised with COVID-19.

Condition or disease Intervention/treatment Phase
Covid19 Drug: AZD1656 Other: Placebo Phase 2

Detailed Description:

The ARCADIA Trial will assess the safety and efficacy of AZD1656 in 150 patients with either Type 1 or Type 2 diabetes who have been hospitalised with COVID-19.

AZD1656 is a glucokinase (GK; hexokinase 4) activator which has been shown to reduce blood glucose for up to 4 months in humans. Diabetic patients admitted to hospital with COVID-19 often present with hyperglycaemia and are particularly vulnerable to progression to severe COVID-19. Treatment with AZD1656 (in addition to their usual care) may provide additional glucose control which could help improve clinical outcomes in both Type 1 and Type 2 diabetic populations.

In addition to its glucose lowering effect, AZD1656 may have additional benefits to COVID-19 patients via its effects on immune function. In many patients with severe COVID-19, an overreaction of the body's own immune system can cause severe problems including damage to the lungs and heart, which can lead to breathing problems necessitating intubation and ventilation. AZD1656 has been shown to activate the migration of T regulatory cells to sites of inflammation in preclinical experiments. This migration of Treg cells to inflamed tissue is crucial for their immune-modulatory function (Kishore et al (2017)). AZD1656 could enhance Treg migratory capacity and may prevent the development of cardiorespiratory complications observed in hospitalised patients with COVID-19, leading to lower requirements for oxygen therapy and assisted ventilation, and reduced incidences of pneumonia and acute respiratory distress syndrome (ARDS).

Diabetic patients hospitalised with COVID-19 will be randomised to receive either AZD1656 tablets or placebo tablets on a 1:1 basis until they are discharged from hospital or until they require intubation/mechanical ventilation. The aim of the study is to determine whether AZD1656 improves clinical outcomes in diabetic patients hospitalised with COVID-19. The World Health Organization (WHO) 8-point Ordinal Scale for Clinical Improvement will be used as the standard methodology for measuring patient outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is a randomised double-blind study. Eligible patients will be randomly assigned to one of two groups (AZD1656 plus usual care or placebo plus usual care) on a 1:1 basis
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double-blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19
Actual Study Start Date : August 12, 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Arm Intervention/treatment
Experimental: AZD1656 (plus Usual Hospital Care)
50mg film-coated tablets at a dose of 100mg BID
Drug: AZD1656
50mg film-coated tablets (at daily dose of 100mg BID)

Placebo Comparator: Matched Placebo (plus Usual Hospital Care)
Matched placebo tablets
Other: Placebo
Matched placebo tablets




Primary Outcome Measures :
  1. Clinical Improvement by Day 14 [ Time Frame: Day 1 to Day 14 ]
    Clinical Improvement measured as the percentage of subjects at Day 14 who are in categories 1-3 according to the WHO 8-point Ordinal Scale for Clinical Improvement, comparing AZD1656 treatment to placebo


Secondary Outcome Measures :
  1. *Title: Clinical Improvement at Day 7, 14 and 21 [ Time Frame: Day 1 to Day 21 ]
    Clinical Improvement measured as the percentage of patients categorised at each severity rating on the WHO 8-point Ordinal Scale at Day 7, Day 14 and Day 21 versus baseline, comparing AZD1656 treatment with placebo.

  2. Glycaemic Control [ Time Frame: Day 1 to Day 21 ]
    Degree of glycaemic control as measured by the need to increase baseline medication requirements or the need to add additional diabetic medications to maintain appropriate blood glucose levels in patients receiving AZD1656 compared with placebo

  3. Occurrence of Adverse Events [ Time Frame: Day 1 to Day 28 ]
    Proportion of Treatment Emergent Adverse Events (TEAEs) leading to study drug discontinuation in patients receiving AZD1656 compared with placebo

  4. Occurrence of Serious Adverse Events [ Time Frame: Day 1 to Day 28 ]
    Proportion of Serious Adverse Events (SAEs) in patients receiving AZD1656 compared with placebo

  5. Duration of Hospitalisation [ Time Frame: Day 1 to Day 21 ]
    Time from hospital admission to hospital discharge (in hours) in patients receiving AZD1656 compared with placebo

  6. Time to Intubation/ Mechanical Intervention [ Time Frame: Day 1 to Day 21 ]
    Time from hospital admission to receiving intubation/mechanical ventilation in patients receiving AZD1656 compared with placebo

  7. Mortality Rate [ Time Frame: Day 1 to Day 28 ]
    Mortality rate in patients receiving AZD1656 compared with placebo.


Other Outcome Measures:
  1. Pharmacokinetic Analysis [ Time Frame: Day 1 to Day 7 ]
    Plasma AZD1656 levels during first 7 days of treatment in patients receiving AZD1656 compared with placebo.

  2. Immunophenotyping Analysis [ Time Frame: Day 1 to Day 21 ]
    Immunophenotyping panel to be conducted by Flow Cytometry: between group comparison (AZD1656 versus placebo)

  3. Immunochemistry Analysis [ Time Frame: Day 1 to Day 21 ]
    Immunochemistry panel to be conducted using the Meso Scale Discovery (MSD) U-Plex multiplex assay.

  4. Cardiac Injury [ Time Frame: Day 1 to Day 21 ]
    Measurement of hsTroponin and NTproBNP to determine extent of cardiac injury in patients receiving AZD1656 compared with placebo

  5. Correlation of clinical outcomes with pre-treatment vitamin D levels (by measurement of 25-hydroxyvitamin D levels). [ Time Frame: Day 1 to Day 21 ]
    Measurement of 25-hydroxyvitamin D levels before treatment to determine whether there is any correlation between baseline vitamin D level and clinical improvement in patients treated with AZD1656 versus placebo.

  6. Correlation of patient ethnicity with clinical improvement [ Time Frame: Day 1 to Day 21 ]
    Sub group analysis of patient ethnicity, to determine whether there is any correlation between patient ethnicity and clinical improvement in patients treated with AZD1656 versus placebo.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or Female.
  2. Aged 18 and older.
  3. Have either Type I or Type II Diabetes Mellitus.
  4. Hospitalised with suspected or confirmed novel coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)) infection at time of enrolment, categorised as stage 3, 4 or 5 on the WHO Ordinal Scale for Clinical Improvement.
  5. Blood glucose level at or above 4 mmol/L.
  6. Able to take oral (tablet) formulation of medication.
  7. Patient is able to provide written informed consent prior to initiation of any study procedures.

Exclusion Criteria:

  1. In the opinion of the clinical team, progression to intubation or mechanical ventilation is imminent and inevitable, within the next 24 hours, irrespective of the provision of treatments.
  2. Patients admitted with primary suspected or proven Mycoplasma pneumoniae, Chlamydia pneumoniae and bacterial pneumonia, who acquired COVID-19 while hospitalized.
  3. Treatment with immunomodulators or anti-rejection drugs within the last 3 months.
  4. Pregnant or breast feeding.
  5. Men, and women of child-bearing potential, unwilling to use highly effective contraception during their participation in the trial and for 2 weeks after study completion.
  6. Anticipated transfer to another hospital which is not a study site within 72 hours.
  7. Known sensitivity to any of the study medication/placebo excipients.
  8. Prior dosing with AZD1656 on a previous clinical trial.
  9. Patients admitted as a result of and receiving immediate treatment for an acute asthmatic attack, acute myocardial infarction, acute cerebrovascular event.
  10. Any known non-COVID-19, non-diabetes related, serious condition which, in the opinion of the clinical team, makes the patient unsuitable for the trial.
  11. Known history of drug or alcohol abuse within previous 12 months of screening.
  12. Known history of HIV, hepatitis C or unresolved hepatitis B or severe liver disease.
  13. Current or planned use of gemfibrozil or any other strong inhibitors of CYP2C8.
  14. Current or previous participation in another clinical trial where the patient has received a dose of an Investigational Medicinal Product (IMP) containing small molecule treatment(s) within 30 days or 5 half-lives (whichever is longer) prior to enrolment into this study, or containing biological treatment(s) within 3 months prior to entry into this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04516759


Contacts
Layout table for location contacts
Contact: Mike Johnson +44 (0)7768335460 info@sgscapital.org

Locations
Layout table for location information
United Kingdom
Barnsley Hospital NHS Foundation Trust Recruiting
Barnsley, United Kingdom
Bradford Teaching Hospitals NHS Foundation Trust Recruiting
Bradford, United Kingdom, BD9 6RJ
North Bristol NHS Trust Recruiting
Bristol, United Kingdom, BS10 5NB
The Dudley Group NHS Foundation Trust Recruiting
Dudley, United Kingdom, DY1 2HQ
Medway NHS Foundation Trust Recruiting
Gillingham, United Kingdom, ME7 5NY
Hull & East Yorkshire NHS Trust Recruiting
Hull, United Kingdom
Barts Health NHS Trust Recruiting
London, United Kingdom, E1 1FR
Royal Free London NHS Foundation Trust Not yet recruiting
London, United Kingdom, NW3 2QG
Penine Acute Hospitals NHS Trust Recruiting
Salford, United Kingdom, M6 8HD
Sheffield Hospitals NHS Foundation Trust Recruiting
Sheffield, United Kingdom, S10 2SB
Somerset NHS Foundation Trust Recruiting
Taunton, United Kingdom, TA1 5DA
Walsall Healthcare NHS Trust Recruiting
Walsall, United Kingdom, WS2 9PS
Sponsors and Collaborators
St George Street Capital
Investigators
Layout table for investigator information
Principal Investigator: Kieran McCafferty, MD Barts & The London NHS Trust
Additional Information:
Layout table for additonal information
Responsible Party: St George Street Capital
ClinicalTrials.gov Identifier: NCT04516759    
Other Study ID Numbers: SGS.1656.201
2020-002211-21 ( EudraCT Number )
First Posted: August 18, 2020    Key Record Dates
Last Update Posted: November 9, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by St George Street Capital:
COVID-19
Diabetes Mellitus
SARS-CoV-2
Regulatory T Cell
Glucokinase